同源 Spikevax 或异源 Vaxzevria-Spikevax 疫苗接种后对 SARS-CoV-2 Delta 变异株诱导产生中和抗体的效果显著。
Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination.
机构信息
Hannover Medical School, Institute of Immunology, Hannover, Germany.
Institute of Molecular and Clinical Immunology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.
出版信息
Eur J Immunol. 2022 Feb;52(2):356-359. doi: 10.1002/eji.202149645. Epub 2022 Jan 7.
Sera of vaccines were assessed by surrogate virus neutralization tests for their capacity to neutralize the SARS-CoV-2 Delta variant. Homologous prime-boost immunization with Moderna's Spikevax as well as heterologous immunization with AstraZeneca's Vaxzevria followed by Moderna's Spikevax were identified as highly potent vaccination regimens for the induction of Delta-neutralizing antibodies.
疫苗血清通过替代病毒中和试验评估其中和 SARS-CoV-2 德尔塔变异株的能力。使用 Moderna 的 Spikevax 进行同源加强免疫以及使用 AstraZeneca 的 Vaxzevria 进行异源免疫后再使用 Moderna 的 Spikevax 被鉴定为诱导德尔塔中和抗体的高效疫苗接种方案。
Zotero 插件